Conditions: Type 2 Diabetic Nephropathy
Keywords: Type 2 diabetes mellitus. albuminuria.
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.

Detailed description:
This study was terminated on 12-Sep-2012; this decision was made due to poor recruitment and overall business strategy. The study was not terminated for safety reasons nor for lack of efficacy.

Arms:
arm 1: None arm 2: 25 mg once daily arm 3: Placebo once daily

Interventions: intervention 1: PF-03882845 intervention 2: PF-03882845 intervention 3: PF-03882845 intervention 4: Spironolactone intervention 5: placebo
Intervention descriptions: intervention 1: 3 mg tablet once daily intervention 2: up to 10 mg tablet once daily intervention 3: up to 30 mg once daily intervention 4: spironolactone 25 mg once daily intervention 5: placebo once daily

Protocol document: